Table 2. Results for various drug classes with focus on under-treatment.

GOLD 2017_CAT	Number of patients	Neither LABA nor LAMA	LABA without LAMA	LABA (mono) without LAMA without LABA + ICS	LAMA without LABA
A	247 (10.8%)	40 (16.2%)	48 (19.4%)	33 (13.4%)	35 (14.2%)
B	1 207 (52.9%)	123 (10.2%)	225 (18.6%)	95 (7.9%)	101 (8.4%)
C	41 (1.8%)	1 (2.4%)	9 (22.0%)	2 (4.9%)	1 (2.4%)
D	786 (34.5%)	22 (2.8%)	96 (12.2%)	37 (4.7%)	38 (4.8%)
Total	2281	146 (6.4%)	105 (4.6%)	39 (1.7%)	38 (1.7%)
	Under-treatment according to 2017 GOLD		Cannot be classified separately

Absolute frequencies and percentages of selected drug classes in the GOLD groups A–D on the basis of CAT. The selection was made with a focus on potential under-treatment. The percentages for the various medications refer to the number of patients in the respective GOLD group, the percentages on the left and lower margins to the analyzable total number of patients (N = 2281). The color codes symbolize an under-treatment (red), or that the appropriateness could not be evaluated by itself (gray; see text and for comparison Table 1).). For a comparison with mMRC see eTable 2. The column totals refer to patients with signs of under-treatment. CAT, COPD Assessment Test; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids; mMRC, modified Medical Research Council